Research programme: marine antibacterial therapeutics - Aphios
Alternative Names: MarinusLatest Information Update: 28 Apr 2023
Price :
$50 *
At a glance
- Originator Aphios Corporation
- Class Antibacterials
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Bacterial infections
Most Recent Events
- 28 Apr 2023 No recent reports of development identified for preclinical development in Bacterial-infections in USA
- 07 Apr 2021 Preclinical development is still ongoing for Bacterial infections in USA (Aphios Corporation website, April 2021)
- 01 Apr 2021 Research programme: marine antibacterial therapeutics - Aphios is available for licensing as of 01 Apr 2021. https://aphios.com/products/therapeutic-products-pipeline/infectious-disease/marinus/